Ecto-nucleotide pyrophosphatase/phosphodiesterase as part of a multiple system for nucleotide hydrolysis by platelets from rats: kinetic characterization and biochemical properties.
In this study, we describe an ecto-nucleotide pyrophosphatase/phosphodiesterase (E-NPP) activity in rat platelets. Using p-nitrophenyl 5'-thymidine monophosphate (p-Nph-5'-TMP) as a substrate for E-NPP, we demonstrate an enzyme activity that shares the major biochemical properties described for E-NPPs: alkaline pH dependence, divalent cation dependence and blockade of activity by metal ion chelator. K(m) and V(max) values for p-Nph-5'-TMP hydrolysis were found to be 106 +/- 18 microM and 3.44 +/- 0.18 nmol p-nitrophenol/min/mg (mean +/- SD, n = 5). We hypothesize that an E-NPP is co-localized with an ecto-nucleoside triphosphate diphosphohydrolase and an ecto-5'-nucleotidase on the platelet surface, as part of a multiple system for nucleotide hydrolysis, since they can act under distinct physiological conditions and can be differently regulated. Thus, 0.25 mM suramin inhibited p-Nph-5'-TMP, ATP and ADP hydrolysis, while 0.5 mM AMP decreased only p-Nph-5'-TMP hydrolysis. Besides, 5.0, 10 and 20 mM sodium azide just inhibited ATP and ADP hydrolysis. Angiotensin II (5.0 and 10 nM) affected only ADP hydrolysis. Gadolinium chloride (0.2 and 0.5 mM) strongly inhibited the ATP and ADP hydrolysis. The E-NPP described here represents a novel insight into the control of platelet purinergic signaling.
Fürstenau
Cristina Ribas
CR
Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Trentin
Danielle Da Silva
Dda S
Barreto-Chaves
Maria Luiza Morais
ML
Sarkis
João José Freitas
JJ
D000244:Adenosine Diphosphate / Q000037:antagonists & inhibitors / Q000502:physiology; D000255:Adenosine Triphosphate / Q000037:antagonists & inhibitors / Q000502:physiology; D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001792:Blood Platelets / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D005682:Gadolinium / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D006868:Hydrolysis; D007700:Kinetics; D008297:Male; D009711:Nucleotides / Q000737:chemistry / Q000378:metabolism*; D010726:Phosphodiesterase Inhibitors; D010727:Phosphoric Diester Hydrolases / Q000737:chemistry / Q000378:metabolism*; D011755:Pyrophosphatases / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism*; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction / Q000187:drug effects / Q000502:physiology; D019810:Sodium Azide / Q000494:pharmacology; D013498:Suramin / Q000494:pharmacology; D013938:Thymidine Monophosphate / Q000031:analogs & derivatives / Q000502:physiology
D009711:Nucleotides; D010726:Phosphodiesterase Inhibitors; D000804:Angiotensin II; C032579:thymidine 5'-4-nitrophenyl phosphate; D013938:Thymidine Monophosphate; D013498:Suramin; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D019810:Sodium Azide; D005682:Gadolinium; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; C038958:gadolinium chloride